mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
Progress
32% Bias Score
Moderna Receives $590 Million for Accelerated Bird Flu Vaccine Development
The U.S. government awarded Moderna an additional $590 million to expedite development of an mRNA bird flu vaccine, bringing the total to $766 million, aiming to expand clinical trials for five subtypes and enhance pandemic preparedness amid 67 confirmed human cases since April 2024, with one death ...
Moderna Receives $590 Million for Accelerated Bird Flu Vaccine Development
The U.S. government awarded Moderna an additional $590 million to expedite development of an mRNA bird flu vaccine, bringing the total to $766 million, aiming to expand clinical trials for five subtypes and enhance pandemic preparedness amid 67 confirmed human cases since April 2024, with one death ...
Progress
36% Bias Score
Three Undervalued Stocks for 2025: Intel, Moderna, and Walgreens
The author analyzes three underperforming stocks—Intel, Moderna, and Walgreens—highlighting their potential for recovery despite 2024 losses due to factors like government subsidies, future drug pipelines, and cost-cutting strategies.
Three Undervalued Stocks for 2025: Intel, Moderna, and Walgreens
The author analyzes three underperforming stocks—Intel, Moderna, and Walgreens—highlighting their potential for recovery despite 2024 losses due to factors like government subsidies, future drug pipelines, and cost-cutting strategies.
Progress
36% Bias Score
Moderna Vaccine Deal Bypasses Australian Assessment
Australia's $2 billion deal with Moderna for onshore mRNA vaccine manufacturing bypasses the Pharmaceutical Benefits Advisory Committee (PBAC) assessment, raising concerns about transparency and cost-effectiveness, prompting an investigation and criticism from health experts and competitors.
Moderna Vaccine Deal Bypasses Australian Assessment
Australia's $2 billion deal with Moderna for onshore mRNA vaccine manufacturing bypasses the Pharmaceutical Benefits Advisory Committee (PBAC) assessment, raising concerns about transparency and cost-effectiveness, prompting an investigation and criticism from health experts and competitors.
Progress
52% Bias Score
Moderna's Norovirus Vaccine Trial Accelerated Amid Severe Winter Outbreak
Moderna's norovirus vaccine is in phase three trials, enrolling ahead of schedule due to a severe winter outbreak, with results expected by late 2024 or 2026. The vaccine targets three common genotypes, aiming to lessen symptoms and hospitalizations in high-risk groups like seniors and healthcare wo...
Moderna's Norovirus Vaccine Trial Accelerated Amid Severe Winter Outbreak
Moderna's norovirus vaccine is in phase three trials, enrolling ahead of schedule due to a severe winter outbreak, with results expected by late 2024 or 2026. The vaccine targets three common genotypes, aiming to lessen symptoms and hospitalizations in high-risk groups like seniors and healthcare wo...
Progress
36% Bias Score
S&P 500's 2024 Gains Mask Significant Underperformance by Key Companies
The S&P 500 index is up 23.8% in 2024, but this masks significant underperformance in some sectors. Walgreens Boots Alliance, Intel, and Moderna are among the worst performers, each losing more than 60% and being replaced in the Dow Jones. These declines are attributed to company-specific challenges...
S&P 500's 2024 Gains Mask Significant Underperformance by Key Companies
The S&P 500 index is up 23.8% in 2024, but this masks significant underperformance in some sectors. Walgreens Boots Alliance, Intel, and Moderna are among the worst performers, each losing more than 60% and being replaced in the Dow Jones. These declines are attributed to company-specific challenges...
Progress
48% Bias Score
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Progress
52% Bias Score